iodine has been researched along with Glial Cell Tumors in 9 studies
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.
diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapy monitoring of glioma after stereotactic iodine-125 brachytherapy (SBT) remains challenging because posttherapeutic changes in magnetic resonance imaging can mimic tumor progression." | 7.79 | [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. ( Bartenstein, P; Belka, C; Eigenbrod, S; Graute, V; Jansen, NL; Kreth, FW; la Fougère, C; Lutz, J; Schwarz, SB; Suchorska, B, 2013) |
| "To augment the therapeutic efficacy of BNCT, we used transferrin-conjugated polyethylene glycol (PEG) (TF-PEG) liposome encapsulating sodium borocaptate and Iomeprol, an iodine contrast agent, with intratumoral convection-enhanced delivery (CED) in a rat glioma tumor model." | 7.77 | Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. ( Doi, A; Hiramatsu, R; Ikeda, N; Kasaoka, S; Kawabata, S; Kuroiwa, T; Maruyama, K; Miyata, S; Miyatake, S; Yamashita, T, 2011) |
| "Gliomas and other brain tumors have evaded durable therapies, ultimately causing about 20% of all cancer deaths." | 5.51 | Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy. ( Hainfeld, JF; Panchal, R; Ridwan, SM; Slatkin, DN; Smilowitz, HM; Stanishevskiy, Y, 2019) |
| "Therapy monitoring of glioma after stereotactic iodine-125 brachytherapy (SBT) remains challenging because posttherapeutic changes in magnetic resonance imaging can mimic tumor progression." | 3.79 | [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. ( Bartenstein, P; Belka, C; Eigenbrod, S; Graute, V; Jansen, NL; Kreth, FW; la Fougère, C; Lutz, J; Schwarz, SB; Suchorska, B, 2013) |
| "To augment the therapeutic efficacy of BNCT, we used transferrin-conjugated polyethylene glycol (PEG) (TF-PEG) liposome encapsulating sodium borocaptate and Iomeprol, an iodine contrast agent, with intratumoral convection-enhanced delivery (CED) in a rat glioma tumor model." | 3.77 | Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. ( Doi, A; Hiramatsu, R; Ikeda, N; Kasaoka, S; Kawabata, S; Kuroiwa, T; Maruyama, K; Miyata, S; Miyatake, S; Yamashita, T, 2011) |
| " Two complimentary SSR approaches have been successfully developed in the past 5 years in our team, and may be promising in high-grade glioma management: iodine-enhanced SSR, with an iodinated contrast agent; and Pt-enhanced SSR; a concomitant radio-chemotherapy treatment with locoregional injection of platinated chemotherapy drugs." | 3.74 | Heavy element enhanced synchrotron stereotactic radiotherapy as a promising brain tumour treatment. ( Adam, JF; Balosso, J; Biston, MC; Boudou, C; Charvet, AM; Elleaume, H; Estève, F; Rousseau, J, 2008) |
| "Comparison of different contrast dosages in adult patients with malignant gliomas studied by computed tomography indicates that 28-42 g of iodine is required for clinically diagnostic results." | 3.66 | Optimal contrast dosage in cranial computed tomography. ( Enzmann, DR; Newton, TH; Norman, D, 1978) |
| "Gliomas and other brain tumors have evaded durable therapies, ultimately causing about 20% of all cancer deaths." | 1.51 | Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy. ( Hainfeld, JF; Panchal, R; Ridwan, SM; Slatkin, DN; Smilowitz, HM; Stanishevskiy, Y, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hainfeld, JF | 1 |
| Ridwan, SM | 1 |
| Stanishevskiy, Y | 1 |
| Panchal, R | 1 |
| Slatkin, DN | 1 |
| Smilowitz, HM | 1 |
| Jansen, NL | 1 |
| Suchorska, B | 1 |
| Schwarz, SB | 1 |
| Eigenbrod, S | 1 |
| Lutz, J | 1 |
| Graute, V | 1 |
| Bartenstein, P | 1 |
| Belka, C | 1 |
| Kreth, FW | 1 |
| la Fougère, C | 1 |
| Miyata, S | 1 |
| Kawabata, S | 1 |
| Hiramatsu, R | 1 |
| Doi, A | 1 |
| Ikeda, N | 1 |
| Yamashita, T | 1 |
| Kuroiwa, T | 1 |
| Kasaoka, S | 1 |
| Maruyama, K | 1 |
| Miyatake, S | 1 |
| FEINDEL, W | 1 |
| YAMAMOTO, YL | 1 |
| MCRAE, DL | 1 |
| ZANELLI, J | 1 |
| Adam, JF | 2 |
| Elleaume, H | 3 |
| Joubert, A | 1 |
| Biston, MC | 2 |
| Charvet, AM | 3 |
| Balosso, J | 2 |
| Le Bas, JF | 2 |
| Estève, F | 3 |
| Rousseau, J | 1 |
| Boudou, C | 1 |
| Le Duc, G | 1 |
| Bertrand, B | 1 |
| Corde, S | 1 |
| Farion, R | 1 |
| Lefaix, JL | 1 |
| Leplat, JJ | 1 |
| Berkvens, P | 1 |
| Berruyer, G | 1 |
| Brochard, T | 1 |
| Dabin, Y | 1 |
| Draperi, A | 1 |
| Fiedler, S | 1 |
| Nemoz, C | 1 |
| Perez, M | 1 |
| Renier, M | 1 |
| Suortti, P | 1 |
| Thomlinson, W | 1 |
| Norman, D | 2 |
| Enzmann, DR | 1 |
| Newton, TH | 2 |
| Stevens, EA | 1 |
| Wing, SD | 1 |
| Levin, V | 1 |
9 other studies available for iodine and Glial Cell Tumors
| Article | Year |
|---|---|
Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Doxorubicin; F | 2019 |
[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma.
Topics: Brachytherapy; Disease-Free Survival; Glioma; Humans; Iodine; Magnetic Resonance Imaging; Positron-E | 2013 |
Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy.
Topics: Animals; Borohydrides; Boron Neutron Capture Therapy; Brain Neoplasms; Contrast Media; Drug Delivery | 2011 |
CONTOUR BRAIN SCANNING WITH IODINE AND MERCURY COMPOUNDS FOR DETECTION OF INTRACRANIAL TUMORS.
Topics: Arsenicals; Bismuth; Brain; Brain Neoplasms; Chlormerodrin; Diuretics; Glioma; Hemangiosarcoma; Iodi | 1964 |
Synchrotron radiation therapy of malignant brain glioma loaded with an iodinated contrast agent: first trial on rats bearing F98 gliomas.
Topics: Algorithms; Animals; Brain Neoplasms; Cell Line, Tumor; Contrast Media; Glioma; Iodine; Male; Radiot | 2003 |
Heavy element enhanced synchrotron stereotactic radiotherapy as a promising brain tumour treatment.
Topics: Animals; Biophysical Phenomena; Biophysics; Brain Neoplasms; Contrast Media; Glioma; Humans; Idoxuri | 2008 |
In vivo K-edge imaging with synchrotron radiation.
Topics: Animals; Brain Neoplasms; Contrast Media; Coronary Angiography; Europe; Gadolinium; Glioma; Humans; | 2000 |
Optimal contrast dosage in cranial computed tomography.
Topics: Brain Neoplasms; Contrast Media; Glioma; Humans; Injections, Intravenous; Iodine; Tomography, X-Ray | 1978 |
Quantitative aspects of contrast enhancement in cranial computed tomography.
Topics: Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Glioma; Humans; Injections, Intravenous; Iodin | 1978 |